What is it about?
A new vaccine candidate for genital chlamydia infection has been evaluated in mice. The findings indicate significant protection against challenge with live chlamydia bacteria intravaginally. The results also indicate protection against the severe complications of genital chlamydia infection, e.g. infertility.
Featured Image
Why is it important?
Chlamydia infection is one of the most common sexually transmitted infections (STI) with a global number of new infections exceeding 100 million per year. It causes tremendous health problems such as upper genital tract inflammations, pelvic pains, infertility and a significant increased risk of acquiring other sexually transmitted infections, e.g. HIV. Antibiotic treatment is availble, but as with other STIs with time there is a risk of development of antibiotic resistance. Many chlamydia infections also pass without symptoms, i.e. the spread will contiue if the chain is not interrupted. The only way to stop unknown infections is via a general vaccination program and there is no vaccine against genital chlamydia infection available today.
Perspectives
It is a first step towards developing a commercially available vaccine against sexually transmitted chlamydia infection. We now continue with refinement of the immunization protocols for optimal protection.
Professor Sören Andersson
Örebro University
Read the Original
This page is a summary of: Protection against genital tractChlamydia trachomatisinfection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen, Apmis, November 2016, Wiley,
DOI: 10.1111/apm.12605.
You can read the full text:
Contributors
The following have contributed to this page
